Preliminary Program

 

All sessions will be held at the Sonesta Philadelphia Downtown Rittenhouse Square located at 1800 Market St, Philadelphia, PA 19103.

SUNDAY, APRIL 26, 2020

2:30pm-3:00Check-in/Registration
3:00–3:15Opening Remarks Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
SESSION I. DRUG DISCOVERY 2.0CHAIR: Walter Kostich, PhD—National Multiple Sclerosis Society
3:15–3:20Session Overview
3:20–3:45Omics to Identify Novel Target for Neurodegenerative Diseases Philip De Jager, MD, PhD—Columbia University
3:45–4:10Stem Cells as “New Chemical Entities”Jacques Galipeau, MD—University of Wisconsin, Madison
4:10–4:35Shift in Medicinal Chemistry: from Organic Chemistry to Synthetic BiologyEdmund Graziani, PhD—Apertor Labs
4:35–4:55SESSION I: PANEL DISCUSSION
5:00–5:30MENTORING SESSION (one-to-one mentoring sessions with field experts - pre-registration required)
5:00–7:00EXHIBITS AND WELCOME RECEPTION

MONDAY, APRIL 27, 2020

7:30–8:30amCheck-in and Continental Breakfast
8:30–8:40Opening Remarks and ADDF Funding Opportunities Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
8:40–8:50National Institute on Aging Alzheimer’s and Related Dementias Translational Research ProgramZane Martin, PhD—National Institute on Aging
8:50–9:00NINDS Opportunities for Translational Research Funding Charles Cywin, PhD—National Institute of Neurological Disorders and Stroke
9:00–9:40KEYNOTE: The Clinical Potential of Senolytic DrugsKirkland James, MD, PhD—Mayo Clinic
9:40–10:00EXHIBITS AND BREAK
SESSION II. DRUG DISCOVERY: FROM TEST TUBE TO ANIMAL STUDIESCHAIR: Nadine Tatton, PhD—The Association for Frontotemporal Degeneration (AFTD)
10:00–10:05Session Overview
10:05–10:30Compound Optimization after Target Identification: From HTS to LeadKurt Brunden, PhD—University of Pennsylvania
10:30–10:55What Can We Still Learn from Studies in Animal Models of Neurodegenerative Disease?Joseph Araujo—InterVivo Solutions
10:55–11:20PK/PD in Preclinical DevelopmentNatasha Penner, PhD—Biogen
11:20–11:40SESSION II: PANEL DISCUSSION
11:40am–12:10pmPOSTER SESSION
12:10–1:00LUNCH
SESSION III. FROM ANIMAL STUDIES TO HUMAN CLINICAL TRIALSCHAIR: Liliana Menalled, PhD—The MJFF
1:00–1:05Session Overview
1:05–1:30Requirements for an IND/ToxicologyKenneth Olivier, PhD—Biotech Primer
1:30–1:55What are Biomarkers and Why Should I Develop Them?John Gerdes, PhD—Rio Pharma
1:55–2:20How Do I Choose the Right Subjects for Clinical Trials in Neurodegenerative Diseases?TBA
2:20–2:40SESSION III: PANEL DISCUSSION —Trends in Clinical Trials
2:40–3:10EXHIBITS AND BREAK
SESSION IV. I WISH I KNEW... (PRECLINICAL) CHAIR: Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
3:10–3:15Session Overview
3:15–3:40Case Study: Challenges in Drug Development for Neurodegenerative DiseaseLeticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
3:40–4:05Case Study: Development of Novel Stress Kinase InhibitorD. Martin Watterson, PhD—Northwestern University
4:05–4:30Case Study: Challenges in Biomarker Development for Huntington's DiseaseDouglas MacDonald, PhD—CHDI Foundation
4:30–4:55Case Study: Development of Small-Molecule Ligands to Target TDP-43Allen Reitz, PhD—ALS Biopharma
4:55–5:15SESSION IV: PANEL DISCUSSION
5:15–6:15EARLY CAREER INVESTIGATOR PANEL: Discuss job opportunities in drug discovery

Moderator: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation

Foundation: Liliana Menalled, PhD—The MJFF and Kuldip Dave, PhD—The ALS Assoc.
Government: Charles Cywin, PhD—NINDS
Biotech: Edward Spack, PhD—MedaRed, Inc
Academia: D. Martin Watterson, PhD—Northwestern University
Pharma: Natasha Penner, PhD—Biogen
6:15–7:30NETWORKING RECEPTION

TUESDAY, APRIL 28, 2020

7:30–8:15Check-in and Continental Breakfast
7:30-8:00MENTORING SESSION (one-to-one mentoring sessions with field experts - pre-registration required)
8:25–8:30Welcome & Opening Remarks: ADDF
SESSION V. WORK WITH THE EXPERT - BREAKOUT SESSIONCHAIR: Elizabeth Mills, PhD—Alzheimer’s Drug Discovery Foundation
8:30–8:35Session Overview
8:35–9:45Breakouts
9:45–10:15EXHIBITS AND BREAK
SESSION VI. I WISH I KNEW... (CLINICAL)CHAIR: Kuldip Dave, PhD—The ALS Association
10:15–10:20Session Overview
10:20–10:45Case Study: O-GlcNAcase Inhibitors for the Treatment of Tauopathies – From Early Discovery to a Clinical Efficacy Trial in PSP PatientsDirk Beher, PhD—Asceneuron
10:45–11:10Case Study: Challenges Associated with Biomarker Development in Neurodegenerative Conditions – “A Commercial Perspective”Iswariya (Ishu) Venkataraman, PhD—Euroimmun
11:10–11:35Case Study: SEMA4D Modulates Blood-Brain Barrier, Microglia, and Inhibits Remyelination in Neurodegenerative DiseaseMaurice Zauderer, PhD—Vaccinex
11:35–12:00Case Study: TBATBA
12:00–12:20SESSION VI: PANEL DISCUSSION
12:20–12:50POSTER SESSION
12:50–1:45LUNCH
SESSION VII. BUILDING THE INFRASTRUCTURE TO COMMERCIALIZE SCIENCE INTO PRODUCTSCHAIR: Alessio Travaglia, PhD—Alzheimer's Drug Discovery Foundation
1:45–1:50Session Overview
1:50–2:15The Handling of Drug Discovery IP and Paths to CommercializationMaria Emanuel, PhD—University of New Hampshire
2:15–2:40Developing your Team and Your Funding StrategyEdward Spack, PhD—MedaRed, Inc.
2:40–3:25SESSION VII: PANEL DISCUSSION—How Do I Get Funded?Moderator: Alessio Travaglia, PhD—ADDF

Panelists:
Liliana Menalled, PhD—The Michael J. Fox Foundation
Kuldip Dave, PhD—The ALS Association
Walter Kostich, PhD—National Multiple Sclerosis Society
Douglas Macdonald, PhD—CHDI Foundation
Nadine Tatton, PhD—AFTD
Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
3:25–3:30Closing RemarksAlessio Travaglia, PhD—Alzheimer's Drug Discovery Foundation